Hypertension in pregnancy

Motha MBC  Jayasundara C

INTRODUCTION

Hypertension, defined as a systolic blood pressure (SBP) ≥140mm Hg and/or diastolic blood pressure (DBP) ≥ 90 mmHg is the commonest medical disorder encountered in pregnancy. It includes women with chronic hypertension (hypertension prior to 20 weeks of pregnancy or present at the booking visit including pre-existing hypertension), gestational hypertension (hypertension presenting after 20 weeks without proteinuria) and pre-eclampsia (hypertension presenting after 20 weeks with significant proteinuria).

MEASUREMENT OF BLOOD PRESSURE

Blood pressure should be measured with the woman seated and feet supported. Measurements should be taken after two to three minutes resting in this position. A standard size cuff should be used for women with an arm circumference of less than 33 cm and a large cuff used for arm circumference above 33 cm. The bladder of the sphygmomanometer should encircle 2/3rds of the upper arm circumference. The cuff should be inflated above 20-30 mmHg of the palpable systolic blood pressure and deflated at a rate of 2 mmHg per second, recording BP to the nearest 2mmHg. Korotkoff phase I and V should be inflation above 20-30 mmHg of the palpable systolic blood pressure and deflated at a rate of 2 mmHg per second, recording BP to the nearest 2mmHg. Korotkoff phase I and V should be referred to the relevant specialist for advise on management of hypertension during pregnancy. Aspirin 75mg daily should be commenced at 12 weeks and continued until the birth of the baby.

GESTATIONAL HYPERTENSION

Hypertension occurring in the second half of pregnancy in a previously normotensive woman, without significant proteinuria or other features of pre-eclampsia, is termed gestational or pregnancy induced hypertension. It complicates 6-7% of pregnancies and resolves post partum. Gestational hypertension should be referred to a secondary care setting for management of pregnancy.

PREECLAMPSIA

Pre-eclampsia usually occurs after 20 weeks gestation and is characterised by significant proteinuria and hypertension. Pre-eclampsia has a complex pathophysiology, the primary cause being abnormal placenta. During normal pregnancy, the villous cytotrophoblast invades the inner third of the myometrium, and spiral arteries lose their endothelium and most of their muscle fibers. These structural modifications are associated with functional alterations, such that spiral arteries become low resistance vessels, and thus less sensitive to vasoconstrictive substances. Abnormal placentation due to suboptimal invasion on the spiral arteries leads to increased uterine arterial resistance with higher sensitivity to vasoconstrictors and thus chronic placental ischemia and oxidative stress. Oxidative stress induces release of substances such as free radicals, oxidized lipids, cytokines, and serum soluble vascular endothelial growth factor into the systemic circulation. These abnormalities are responsible for endothelial dysfunction. Perfusion is decreased to virtually all organs, which is secondary to intense vasospasm due to an increased sensitivity of the vasculature to pressor agents. Perfusion is further compromised by activation of the coagulation cascade, especially platelets, with attendant microthrombi formation. Additionally, plasma volume is decreased by loss of fluid from the intravascular space, further compromising organ blood flow.

An automated reagent strip reading device could be used to detect proteinuria and a result of 1+ or more should prompt quantification of proteinuria using a spot protein:creatinine ratio or a 24 hour urine collection. Presence of significant proteinuria is diagnosed when the urinary protein:creatinine ratio is greater than 300mg/mmole or 24 hour urine collection shows greater than 300mg of protein.

Overall pre-eclampsia complicates 5-6% of pregnancies, but this figure increases up to 25% in women with pre-existing hypertension. When gestational hypertension is diagnosed after 36 weeks of pregnancy, the risk falls to 10%. An estimated 50 000 women die annually from pre-eclampsia worldwide due to placental abruption, intra-abdominal haemorrhage, cardiac failure, and...
multi-organ failure. Women with hypertension should be advised to seek immediate care if they develop symptoms suggestive of preeclampsia which include severe headache, vision disturbances such as blurring or flashing before the eyes, right hypochondrial or epigastric pain, vomiting or sudden swelling of the feet or face.

In the presence of any of the above features and significant proteinuria the woman should be admitted and blood pressure closely monitored. The blood pressure should be monitored four times a day. The full blood count, renal functions including electrolytes and hepatic transaminases should be monitored twice weekly in those with mild hypertension and thrice weekly in those with moderate hypertension and beyond.

Severe preeclampsia is diagnosed in the presence of severe hypertension and proteinuria or mild or moderate hypertension with one of severe headache, blurring of vision or flashing of lights, right hypochondrial pain, vomiting, papilloedema, sustained clonus, right hypochondrial tenderness, HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome, platelet count <100 x10⁹/litre and AST or ALT >70 IU/L.

In women with severe preeclampsia, maintenance fluids should be limited to 80ml/hour.

**ECLAMPSIA**

An eclamptic seizure may be preceded by severe preeclampsia or mild hypertension without proteinuria. An eclamptic seizure usually lasts 60-90 seconds. A postictal phase may be present with confusion and agitation. The timing of an eclamptic seizure can be antepartum (53 percent), intrapartum (19 percent), or postpartum (28 percent). Initial management of an eclamptic seizure includes protecting the airway and minimizing the risk of aspiration by placing the woman on her left side, suctioning her mouth, and administering oxygen. Magnesium sulphate is the drug of choice in preventing further seizures. Magnesium sulphate should also be considered in women with severe preeclampsia in whom birth is planned within 24 hours. A loading dose of 4g of magnesium sulphate should be administered intravenously over 5 minutes, followed by an infusion of 1g per hour maintained for 24 hours. Recurrent seizures are managed with a repeat dose of 2.4 g given over 5 minutes.

**WHEN TO START ANTIHYPERTENSIVES**

Those with mild (systolic blood pressure 140-149 mmHg and diastolic 90-99 mmHg) hypertension could be managed as outpatients with advice on weekly measurement of blood pressure. Those with moderate hypertension (systolic blood pressure 150-159 mmHg and diastolic 100-109 mmHg) should be commenced on medication with one of oral labetolol, methyldopa or nifedipine (slow release) tablets. The mortality and morbidity of women with severe hypertension (> 160/110 mm Hg), usually secondary to severe preeclampsia, remain considerable. Management of severe hypertension involves adequate blood pressure control, often using parenteral agents. Parenteral hydralazine or labetalol are considered first line agents. A Cochrane review showed no evidence that one parenteral agent had superior effectiveness. Available data also favour the use of oral nifedipine in the management of severe hypertension in pregnancy.

Because of contraction of circulating plasma volume, women may be very sensitive to relatively small doses of antihypertensive agents, risking abrupt reductions in blood pressure. Good control of hypertension in severe preeclampsia does not halt the progression of the disease, but reduces the incidence of complications such as cerebral haemorrhage.

**MEDICATIONS USED IN HYPERTENSION OF PREGNANCY**

The long term safety for the fetus with use of methyldopa has been well demonstrated, but recommendations suggest avoiding the use of methyldopa in the postpartum period because it can cause depression in some women. However, it is only a mild antihypertensive agent and has a slow onset of action (three to six hours), and therefore may be less effective for severe hypertension. Methyldopa is started at a dose of 250mg or 500 mg bd and increased up to a maximum of 2g per 24 hours. The drug may result in an elevation of liver transaminases (in up to 5% of women) or a positive Coomb’s test (although haemolytic anaemia is uncommon).

Oral labetolol should be commenced at a dose of 100 mg twice daily and increased up to 1200 mg of a total daily dose. Slow release nifedipine should be commenced at a dose of 20mg daily and increased up to 120mg daily. Hydralazine should be commenced at a dose of 5 mg IV and repeated every 30 minutes to a maximum of 20 mg IV (or 30 mg IM). It could also be given as an infusion at a rate of 50-150 µg/minute. Hydralazine should be given after a colloid challenge to reduce the reflex tachycardia, and abrupt hypotension, precipitated by vasodilatation of a volume contracted circulation.

**TARGET BLOOD PRESSURE**

Overzealous blood pressure control may lead to placental hypoperfusion, as placental blood flow is not autoregulated, which in turn will compromise the fetus. Once treatment is started, target blood pressure is also controversial, but many practitioners advocate a mean arterial pressure of 125 mmHg. Eg: a blood pressure 150/100 mm Hg.

In women with chronic hypertension and absence of target organ damage, the aim is to maintain BP below 150/100 mmHg during pregnancy, while in the presence of target organ damage secondary to chronic hypertension (Eg: renal impairment, left ventricular hypertrophy, hypertensive retinopathy) the blood pressure should be maintained below 140/90 mmHg. There is no evidence that pharmacological treatment of chronic or gestational hypertension protects against the development of pre-eclampsia. Changes in diet or bed rest have not been shown to provide maternal or fetal benefit.
The blood pressure should be monitored weekly in mild hypertension, twice weekly in moderate hypertension and four times a day in severe hypertension. In women with mild hypertension presenting before 32 weeks, or at high risk of pre-eclampsia, blood pressure and urine for significant proteinuria should be assessed twice weekly.

**ANTEnatal Fetal Monitoring**

Hypertension in pregnancy and especially preeclampsia is associated with increased fetal morbidity and mortality. These include oligohydramnios, fetal growth restriction (FGR), absent or reversed end diastolic flow in the umbilical artery by doppler velocimetry, placental abruption and even fetal demise. So it’s vital that fetal morbidity is detected early in hypertensive disease of pregnancy. As much of fetal morbidity and mortality in chronic hypertension is due to associated superimposed preeclampsia or fetal growth restriction, the management should be focused on detecting these early. Fetal growth, amniotic fluid volume assessment and umbilical artery doppler should be assessed at 28-30 weeks and 32-34 weeks. If there is no abnormality at these scans further testing can be deferred unless new problem arises. If there is a clinical indication an earlier ultrasound assessment can be done. Antenatal non stress test (CTG) is indicated only if there are abnormal fetal movements.

In pregnancy induced hypertension (PIH) and mild preeclampsia, a growth scan, amniotic fluid assessment and an umbilical artery Doppler (UAD) is indicated if diagnosed prior to 34 weeks but its value is controversial if its diagnosed after 34 weeks and if the fetal growth was normal prior to 34 weeks. If FGR is suspected in a preeclamptic women, the fetal growth assessment should be performed serially every three weekly to detect worsening FGR. If FGR is worsening more frequent amniotic fluid assessment and Doppler studies of umbilical arteries are needed. A CTG is beneficial if there is reduced fetal movements, unexpected antepartum hemorrhage, abdominal pain and if there is a deterioration in maternal condition.

If decided to deliver prior to 34 weeks, a course of antenatal corticosteroids for fetal lung maturation is recommended as it’s proven to reduce the incidence of respiratory distress syndrome and intraventricular haemorrhages in preterm neonates.

**Planning Delivery**

Delivery is the only cure for hypertension in pregnancy. In a woman with preeclampsia, delivery should be planned when the woman reaches 36-37 weeks of gestation, irrespective of the degree of preeclampsia. Expectant management is also not justified if preeclampsia occurs prior to 14 weeks in view of high risk of maternal complications and poor fetal prognosis. At 34-37 weeks, management depends on the severity of pre-eclampsia. Expectant management is possible for mild preeclampsia to limit the risk of induced preterm delivery, but for severe preeclampsia, delivery remains the rule due to the increased risk of maternal and fetal complications. For patients with severe preeclampsia between 24 and 34 weeks of gestation, data are insufficient to recommend “interventionist” versus expectant management.

**Intrapartum Care**

Antihypertensives should be continued in labour. During labour blood pressure should be measured hourly in women with mild and moderate hypertension and continuously in those with severe hypertension. In women with mild, moderate and severe hypertension in whom blood pressure is controlled the second stage of labour need not be prolonged. Operative delivery should be considered in women who remain to have severe hypertension in the second stage of labour that is poorly responsive to antihypertensives.

Fetal monitoring in labour does not differ much from monitoring in any other high risk pregnancy, and if available continuous fetal monitoring should be considered especially if there is associated FGR. Fetal indication for expeditious delivery include repetitive late decelerations, severe variable decelerations and short term variability less than 3 bpm.

**Post Natal Management**

Blood pressure should be measured daily in the first two days after birth, and at least once between day 3 and 5. In women with preeclampsia and on treatment during the antenatal period, blood pressure should be monitored 4 times a day while an inpatient. Antihypertensive treatment may be reduced when the blood pressure falls below 130/80 mmHg. Women who have not been on antihypertensives during the antenatal period and whose blood pressure is 150/100 mmHg or above should be commenced on antihypertensives.

In women who are breastfeeding, labetolol, nifedipine, captopril, enalapril, atenolol and metoprolol can be used safely.

In women with preeclampsia, serum creatinine, platelet count and serum transaminases should be performed after 48-72 hours of birth and repeated if results are abnormal. Proteinuria should be assessed at 6 weeks in women with preeclampsia and if elevated should be reviewed with repeat assessment at 3 months. If proteinuria persists referral to a renal specialist should be sought.

On discharge, advise should be given with regard to frequency of blood pressure assessment, thresholds for stopping or starting treatment and when to attend for a review. In women who had preeclampsia during the antenatal period and were on treatment, blood pressure should be monitored every 1-2 days until antihypertensives are stopped. Arrangements should be made for medical review of women who remain on antihypertensive treatment 2 weeks after birth and a 6 week review for all women with gestational hypertension. Those who remain hypertensive beyond 6 weeks postpartum should be referred to a medical clinic for specialist assessment of hypertension and follow up care.
REducing the risk of Hypertensive Disorders

Low dose aspirin has been shown to reduce the relative risk of pre-eclampsia by 19%. Women with hypertensive disease during a previous pregnancy, chronic kidney disease, systemic lupus erythematosus or antiphospholipid syndrome, type 1 or 2 diabetes mellitus and chronic hypertension should be commenced on 75 mg of aspirin daily from 12 weeks onwards until the birth of the baby. Women with more than one moderate risk factor which includes first pregnancy, age equal or more than 40 years, pregnancy interval of more than 10 years, body mass index of more than 35 kg/m², family history of preeclampsia and multiple pregnancy should also be commenced on a similar regimen of aspirin.

Risk of recurrence of Hypertensive Disorder in Subsequent Pregnancy

Women who experience hypertension in a first pregnancy are at increased risk in a subsequent pregnancy. Certain factors influence this risk. The earlier the onset of hypertension in the first pregnancy, the greater the risk of recurrence. The type of hypertensive disorder influences recurrence. One study reported a recurrence risk of 19% for gestational hypertension, 32% for pre-eclampsia, and 46% for pre-eclampsia superimposed on pre-existing chronic hypertension. In addition, severe isolated IUGR has been identified as a risk factor for developing hypertension in a subsequent pregnancy. In women with preeclampsia, the risk of preeclampsia in a future pregnancy is 1 in 6. However, the risk rises to 1 in 4 in the presence of a history of severe preeclampsia, HELLP syndrome or eclampsia prior to 34 weeks and 1 in 2 if birth occurred before 28 weeks.

Approximately 20% of women with pre-eclampsia develop hypertension or microalbuminuria during long-term follow-up, and the risk of subsequent cardiovascular and cerebrovascular disease is doubled in women with pre-eclampsia and gestational hypertension compared with age-matched controls. Children born after pre-eclamptic pregnancies and who are relatively small at birth, have an increased risk of stroke, coronary heart disease, and metabolic syndrome in adult life.

References